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ABSTRACT: We report two series of novel cephalosporins
that are bactericidal to Mycobacterium tuberculosis alone of the
pathogens tested, which only kill M. tuberculosis when its
replication is halted by conditions resembling those believed to
pertain in the host, and whose bactericidal activity is not
dependent upon or enhanced by clavulanate, a β-lactamase
inhibitor. The two classes of cephalosporins bear an ester or
alternatively an oxadiazole isostere at C-2 of the cephalosporin
ring system, a position that is almost exclusively a carboxylic
acid in clinically used agents in the class. Representatives of the series kill M. tuberculosis within macrophages without toxicity to
the macrophages or other mammalian cells.
■ INTRODUCTION
Antibiotics that rapidly kill Mycobacterium tuberculosis in axenic
culture require months to years to produce the same result in
tuberculosis (TB) patients. Accordingly, TB treatment lags far
behind that of other bacterial diseases in terms of treatment
duration, number of antibiotics required, toxicity to the host,
and cure rates. Although new drugs such as oxazolidinones
(linezolid, Pfizer),1 diarylquinolines (bedaquiline, Janssen),2
and nitroimidazoles (e.g., delamanid)3 offer hope of shortening
TB therapy and reducing mortality in patients whose TB is
resistant to the standard regimen, there is an urgent need to
discover additional anti-TB drugs.
Even when M. tuberculosis is genetically sensitive to existing
drugs, a small fraction of a replicating population survives
exposure to each such drug in vitro. Such bacteria are termed
“persisters”. They display class I phenotypic tolerance4 in that,
when the drug is removed and the persisters are allowed to
replicate, application of the drug at the same concentration
again kills the vast majority. Mechanisms of class I persistence
range from temporary nonreplication of a small subpopulation5
to heterogeneous expression of proteins that activate prodrugs
and misincorporation of amino acids into proteins.6−9
Genetically susceptible M. tuberculosis can also display class II
phenotypic tolerance when external stresses, such as those
imposed by the host immune system, prevent most of the
population from replicating.4,10−12 Ideally, TB should be
treated with a combination of drugs such that bacteria
displaying class I phenotypic tolerance to any one of them
are killed by at least one of the others, and at least one of the
drugs can kill nonreplicating M. tuberculosis that display class II
phenotypic tolerance.
Some of the conditions in the host that can drive M.
tuberculosis into replication arrest and class II phenotypic
tolerance include residence in interferon γ (IFNγ)-activated
macrophages that traffic the bacilli to acidified phagosomes and
expose them to nitrosative and oxidative stress13−15 or release
of M. tuberculosis into the hypoxic milieu of necrotic
granulomas.16 The search for compounds active against
nonreplicating M. tuberculosis has been pursued in a variety of
in vitro nonreplicating models.17−30 We recently developed a
high throughput screening platform to identify small molecules
that kill class II persistent M. tuberculosis that are rendered
nonreplicating by a combination of four host-relevant
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conditions:13−15,21,31−35 low pH (5.0), a flux of nitric oxide
(generated from 0.5 mM nitrite at that pH), hypoxia (1% O2),
and low concentrations of a fatty acid (0.05% butyrate) as the
carbon source instead of the conventional carbon sources
dextrose and glycerol.21,36 Here, we report that this screening
protocol has led to the discovery of the first cephalosporins, to
our knowledge, that are selectively active against bacteria in a
nonreplicating state. We describe an initial analysis of their
structure−activity relationship.
■ RESULTS
Identification of Cephalosporins Active on Non-
replicating M. tuberculosis. A high-throughput screening
campaign against replicating and nonreplicating M. tuberculosis
was carried out using a library of compounds from an in-house
screening collection assembled at the University of Kansas. This
screen led to the identification of three cephalosporin esters37
(1−3, Figure 1a) whose activity was unique to nonreplicating
M. tuberculosis. For comparison, cephalexin 4, a broad-spectrum
antibiotic in clinical use, was also tested in the multistress
nonreplicating model but found to be inactive. The three hit
molecules were resynthesized to >96% purity and displayed
MIC90s against nonreplicating M. tuberculosis of 1.8−2.7 μg/mL
and 0.5−1.1 μg/mL during exposures lasting 3 or 6 days,
respectively (Table 1). Initial results were obtained with a strain
of M. tuberculosis whose dual auxotrophy for pantothenate and
lysine increases its safety for laboratory personnel,38,39 and key
results for select molecules were verified using virulent, wild-
type M. tuberculosis H37Rv. Given the propensity of β-lactams
for inoculum effects,40 we also determined the MIC90s against
nonreplicating M. tuberculosis using a 10-fold lower inoculum of
A580 of 0.01. The results at 3 days (0.7−3.1 μg/mL) were
similar to those found for the higher inoculum cultures exposed
for 6 days. Activity against replicating M. tuberculosis and against
human HepG2 hepatoma cells was not seen up to the highest
concentration tested (100 μg/mL), and the best selectivity
index was ≥250. Thus, the activity of these compounds against
M. tuberculosis was directly dependent on time of exposure and
the state of nonreplication, inversely dependent on concen-
tration of the bacteria, and selective for M. tuberculosis over
human cells.
Stability in Cell-Free PBS and Nonreplicating Me-
dium. Because some molecules are chemically unstable in the
multistress model of nonreplication,21,35,36 compounds 1 and 2
were tested and found to be stable for up to 6 days in cell-free
PBS and nonreplicating medium containing or omitting
NaNO2 (Figure 2a and b). However, 3 was unstable in cell-
free nonreplicating medium containing NaNO2 (Figure 2c;
summarized in Table 1). For comparison, cephalexin was
partially unstable in cell-free PBS and stable in cell-free
nonreplicating medium either containing or lacking NaNO2
(Figure 2d).
Structure−Activity Relationship (SAR) Studies. These
promising results prompted us to undertake an initial
structure−activity relationship survey. For each new analogue,
we determined the activity against Mtb under both non-
Figure 1. Structures of (a) cephalosporins 1−3 selectively active on nonreplicating M. tuberculosis, (b) for an inactive analogue, the clinically used
antibiotic cephalexin, and (c) the C-2 oxadiazole cephalosporin 5.




























NR medium + 0.5
mM NaNO2
1 1.76 1.05 0.90 0.64 >100 >75.69 80 100 100
2 2.61 0.52 3.11 n.t.a 55.44 >100 80 100 100
3 2.69 0.45 0.7 n.t.a >100 >100 100 100 40
cephalexin 4 61.35 70.42 97.93 73.04 33.99 >100 50 100 100
an.t. = not tested.
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replicating (NR) and replicating (R) conditions. In addition,
each compound was assayed for cytotoxicity against HepG2
cells. For the present discussion, analogues are presented in
Tables 2−5 according to the chemical class investigated.
To test if the ester moiety in compounds 1−3 was essential
for activity, we synthesized five free acid analogues of 1 (9) or
related molecules and tested three commercially available
cephalosporins bearing C-2 carboxylic acids (cephalexin,
cefdinir, and cephalothin). The activity of all the cephalosporin
carboxylates tested against nonreplicating M. tuberculosis ranged
from ∼50 to >100 μg/mL (Table 2), signifying the importance
of an ester moiety at C-2. To determine if additional functional
groups could be tolerated at this position, we prepared and
tested analogues containing various amides, alcohols, and ethers
at C-2 (Table 2, compounds 5−18). All were found to be
inactive. However, replacement of the ester moiety by the
isosteric 1,2,4-oxadiazole in analogue 5 resulted in a compound
that was close in activity to 1 (Figure 1c and Table 2).
Moreover, compound 5 was stable in cell-free nonreplicating
medium containing NaNO2 (Figure 3).
To determine if simply adding ester groups or an oxadiazole
to C-2 of a classical cephalosporin would confer activity against
nonreplicating M. tuberculosis, we made cephalexin analogues
4a−c bearing such modifications. Testing determined that
analogues 4a and 4c were poorly active against nonreplicating
M. tuberculosis and completely inactive against replicating M.
tuberculosis (Table 3). n-Propyl ester 4b was slightly more
active with an NR-MIC90 of 15.5 μg/mL.
Given these results, we chose to concentrate on exploring the
effect of C-2 and C-7 amino substitution in two series of
analogues: the esters (Table 4) and the oxadiazoles (Table 5).
All compounds were synthesized as summarized in Scheme 1.
Esters were generated from commercially available 7-amino-
deacetoxycephalosporanic acid (7-ADCA) by amidation,
followed by esterification. The oxadiazole series was prepared
by installing the desired oxadiazole onto the C-2 of carboxylic
acid A41 as shown in Scheme 1 below. Compounds were
typically purified by mass-directed HPLC fractionation and
rendered in purities of ≥95% for biological evaluation.
Numerous analogues in both series of compounds were
active against nonreplicating M. tuberculosis. The activity
profiles of these molecules were responsive to these basic
chemical changes, which suggested that the compounds were
exerting their activity through action at a discrete cellular target.
For example, a preference for longish and unbranched esters at
C-2 was generally observed with ethyl, propyl, and butyl esters
being preferred. Activity was sharply diminished for analogues
containing propargyl groups at this position (e.g., compounds
4, 6, and 22), although benzyl esters were tolerated
(compounds 14, 24, and 29). Recalling that cephalexin
analogues 4a and 4b containing a side chain bearing a primary
amine were poorly active, we concentrated our initial SAR on
neutral C-7 amide moieties (although the single C-7 propyl
amine examined, compound 3, did have significant activity).
Most of the compounds examined bore a substituted 3-
phenylpropamide side chain or its ethereal analogue (e.g.,
compound 13). We also observed that moving the double bond
from the Δ2,3 to the Δ3,4 had only a modest effect (cf.
compounds 34 and 35).
Among the C-2 oxadiazoles (Table 5), similar trends were
observed with a few addenda. Here, a wider range of
carbamates, including a single carbothioate, were prepared
and found to be active (compounds 14−17). In this series, we
noted that although compounds bearing para electron-with-
drawing substituents retained excellent potency, in many cases
measurable levels of cellular toxicity were also observed.
Particularly notable examples included some p-Cl and 3,4-
dichloro analogues (compounds 5, 12, 21, and 29).
Physicochemical Properties and Metabolic Stability.
Compounds 1 and 5 were chosen as representative molecules
of the alkyl ester and oxadiazole classes of cephalosporins that
are active against nonreplicating M. tuberculosis, whereas
cephalexin, cefdinir, and cephalothin were chosen as
representatives of cephalosporins lacking such activity. The
active cephalosporins shared higher values for clogP and pKa,
whereas other properties such as H-bond donors, H-bond
acceptors, molecular weight, heavy atom count, and rotatable
bonds were similar (Table 6).
We next determined the hydrolytic stability of these
compounds under strongly acidic conditions, such as would
be encountered in the stomach. Both 1 and 5 were more stable
at pH 2 (100% remaining after 4 h) than cephalexin (∼74%
remaining) (Table 7), whereas all three compounds were stable
at pH 7 and degraded in base (pH 12). Compound 5 and
cephalexin were soluble at 84 and 76 μM at pH 7.4,
respectively, whereas 1 was less soluble at 23 μM (Table 7).
Parallel artificial membrane permeability assays (PAMPA)
predicted that both 1 and 5 would be membrane permeable
(Table 8). However, unlike cephalexin, both 1 and 5 were
rapidly metabolized by mouse liver microsomes (Table 8).
Compounds 1 and 5 were less susceptible to metabolism by
human liver microsomes with half-lives of ∼80 min and CLint
values suggestive of slow metabolism (Table 8).
Next, we assessed the stability of compounds 1 and 5 in
mouse plasma to determine the feasibility of testing these
compounds for activity in a mouse model of tuberculosis. Both
compounds 1 and 5 were completely transformed in mouse
plasma in <5 min (Figure 4a). In human plasma, compounds 1
and 5 had half-lives of approximately 2−3 h (Figure 4b).
Figure 2. Cell-free stability of primary screening hits. Molecules were
incubated at 37 °C in PBS (blue) or nonreplicating medium without
(orange) or with (red) NaNO2. Data are averages of replicate samples
± standard deviation.
Journal of Medicinal Chemistry Featured Article
DOI: 10.1021/acs.jmedchem.5b01833
J. Med. Chem. 2016, 59, 6027−6044
6029
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Cephalexin 4 was stable in plasma from both species (Figure 4a
and b).
Selective Bactericidal Action of Cephalosporins on
Nonreplicating M. tuberculosis. Narrow spectrum bacter-
icidal activity is preferred for TB drugs for two reasons. First,
TB treatment is protracted, and long-term exposure to broad-
spectrum antibacterial agents can precipitate severe and
sometimes fatal intestinal dysfunction, such as that caused by
overgrowth of Clostridium dif f icile. Second, efficacy of a given
drug against other bacterial infections can prompt its use in the
community, including in people who have undiagnosed TB.
Monotherapy of TB often selects for emergence of genetically
resistant strains. The spread of such strains in the community
would render the new drug progressively less useful for the
treatment of TB. Hence, it was important to test the
antimicrobial spectrum of the new cephalosporins against
other bacteria. Compounds 1 and 5 had MIC90s > 100 μg/mL
against replicating Pseudomonas aeruginosa, Escherichia coli,
Staphylococcus aureus, Mycobacterium smegmatis, and Mycobacte-
rium bovis BCG as well as against the fungus Candida albicans
(Figure S1).
To determine the extent of bacterial kill, we exposed
nonreplicating wild-type M. tuberculosis at an OD580 of 0.01
(low inoculum) to 1 and 5 for 7 days (Figure 5). At ∼ 0.7−0.8
μg/mL, both compounds reduced colony-forming units
(CFUs) by 2 log10. Compounds 1 and 5, at 3 and 10 μg/
mL, respectively, reduced CFU to the extent that there were no
recoverable colonies when 10 μL of undiluted sample was
plated (≥3.4 log10 kill). Thus, no class I phenotypic tolerance
was observed. Bactericidal activity of 1 was not enhanced by the
addition of a β-lactamase inhibitor, clavulanate, and addition of
clavulanate did not lead to activity of 3, 2, or 1 against
replicating M. tuberculosis (data not shown). In contrast,
clavulanate enhanced the replicating MIC90 of Meropenem 4-
fold.
Representative cephalosporins (compounds 5, 12e, 12i, 18d,
19d, 21b, 22c, and 23) from the preliminary SAR campaign
(Tables 2−5) were tested for activity against nonreplicating
wild-type M. tuberculosis. Analogues derived from compounds 1
and 5 were bactericidal in this assay (Figure S2).
Reactive Nitrogen Species Enhance Bactericidal
Activity of 1 and 5 against Nonreplicating M. tuber-
culosis. The activity of 1 against nonreplicating M. tuberculosis
increased in relation to the concentration of NaNO2 (Figure
6a), whereas that of rifampicin did not at ≤0.5 mM NaNO2
(Figure 6b). At 1 mM NaNO2, double the concentration used
in the nonreplicating screening, we observed nitrite-dependent
killing with rifampicin as well. We then tested both 1 and 5 for
nitrite-dependence by coupling the outgrowth to a CFU-
surrogate assay (charcoal agar resazurin assay; CARA)42 that
determines the approximate concentration of compound
leading to ≥2−3 log10 CFU reduction as reflected by the
ability of survivors to convert resazurin to a fluorescent product.
Both 1 and 5 decreased fluorescence in a dose-dependent
manner that was strongly enhanced by the addition of NaNO2
(Figure 6c and d). As observed for many of the β-lactams in
this study, the activities of both 1 and 5 were more potent at a
10-fold lower inoculum of 0.01 and 7-day exposure (Figure 6d).
Both compounds displayed nitrite-independent activity at the
lower inoculum (Figure 6c and Figure 6d). Thus, nitrite
contributed to a 32- to 64-fold enhancement of 1’s activity, but
activity was not strictly dependent on an exogenous source of
nitrite (Figure 6d).
Table 2. continued
aThese data were from a 3-day exposure to compound. bn.d. = not determined. n.t. = not tested.
Figure 3. Cell-free stability of 5. Compound 5 was incubated at 37 °C
in PBS (blue) or nonreplicating medium without (orange) or with
(red) NaNO2. Data are averages of replicate samples ± standard
deviation.
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Nonreplicating-Active Cephalosporins Kill M. tuber-
culosis in Macrophages. Wild-type M. tuberculosis is typically
growth-arrested, or replicates slowly, in activated macrophages,
due in part to phagosomal acidification and macrophage
production of reactive nitrogen species (RNS).13,14 The
multistress nonreplicating assay conditions were designed in
part to mimic this phagosomal microenvironment.21,35 We
hypothesized that cephalosporins active in the nonreplicating
model might be bactericidal against intracellular M. tuberculosis.
To test this, we stimulated mouse bone marrow-derived
macrophages with IFNγ, or left them unstimulated, infected
them with wild-type M. tuberculosis, and treated them with 1, 5,
or diluent alone. We observed approximately 1−2 log10 CFU
reduction of intracellular M. tuberculosis in activated macro-
phages treated with 1 or 5 with no apparent toxicity to the
macrophages. Compound 5’s bactericidal activity against
intracellular M. tuberculosis was strictly IFNγ dependent (Figure
7a and b).
■ DISCUSSION
To our knowledge, this is the first report of β-lactams that only
kill a given bacterium when it is nonreplicating, and the first
report of β-lactams with activity against any one bacterial
species that lacks broad-spectrum antibacterial activity. Early
studies by Tuomanen et al. demonstrated that although many
β-lactams lack activity against nongrowing cells, a minority
killed starved, nonreplicating Escherichia coli and Streptococcus
pneumonia.43,44 Similar findings were recently observed in M.
tuberculosis, as the combination of Meropenem and the β-
lactamase inhibitor clavulanate killed both replicating and
hypoxic, nonreplicating M. tuberculosis.45 Meropenem-clavula-
nate lacked activity against nonreplicating M. tuberculosis in the
conditions studied here. In addition to hypoxia, our conditions
included a low pH, a flux of reactive nitrogen species, and a
fatty acid carbon source. Faropenem was also reported to kill
both replicating and nongrowing M. tuberculosis.46 Like
Meropenem, faropenem was inactive in our multistress model
of nonreplication. The novel cephalosporins described here did
not acquire activity against replicating M. tuberculosis when we
included clavulanate in the assays.
Structurally, the two main classes of compounds explored
herein differ from clinically used cephalosporins by the lack of a
carboxylic acid moiety at C-2 (a notable exception being the
prodrug cefuroxime axetil), and indeed, we showed that
carboxylic acid 9 is inactive against nonreplicating Mtb. Early
in this project, we considered whether the screening hit propyl
ester was functioning as a prodrug, but the successful
Table 3. C-2 Ester and Oxadiazole Analogues of Cephalexin
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replacement of this moiety with the corresponding oxadiazole
renders this possibility unlikely. A hydrophobic moiety at this
position is tolerated, as seen with the n-propyl ester and
oxadiazole, and possibly preferred, given the fact that the C-2
hydroxymethyl analogue 10 is inactive. Polarity at this position
also plays a role given the inactivity of the amide analogous to
the active esters. In the preliminary SAR pursued to date, we
have also ascertained that biological activity is affected by the
amide moiety attached to the central cephalosporin nucleus
with chains ending in electron-poor aromatic rings being
preferred and a moderate dependence of activity on the length
of the chain leading to this point. The role of the β-lactam itself
is currently ambiguous; although we know that hydrolytic
cleavage of this ring results in an inactive compound, it is not
clear whether this is because the β-lactam is essential per se, i.e.,
in analogy to the generally accepted mechanism of most β-
lactams, which involve covalent binding of this group to the
target protein, or because of a structural alignment resulting
from the cephalosporin ring system.
A question of pressing interest is the molecular target that
renders these cephalosporins profoundly active against M.
tuberculosis in a nonreplicating state. Experiments to address
this are underway by a variety of approaches but have not yet
yielded an answer, although we note that our observation of
structure−activity relationships is consistent with action
through one or more specific targets. The canonical role of
β-lactams in killing replicating bacteria has been widely
accepted as the arrest of peptidoglycan biosynthesis. Disruption
of the balance between new peptidoglycan synthesis and
peptidoglycan cleavage by hydrolases leads to cellular lysis47,48
due to a futile cycle in the synthetic pathway.49 The sensitivity
of hypoxic M. tuberculosis to Meropenem and clavulanate, albeit
significantly less than the sensitivity of replicating M. tuber-
culosis, suggests that M. tuberculosis may require peptidoglycan
Table 4. continued
aThese data were from a 3-day exposure to compound. bn.d. = not determined.
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biosynthesis to survive the hypoxic state.45 In addition to
classical D,D-transpeptidases that catalyze the formation of 4′
→ 3′ peptidoglycan cross-links, M. tuberculosis may use at least
five L,D-transpeptidases (LdtMT1−LdtMT5; LDTs) for peptido-
glycan 3′ → 3′ cross-linking. The 3′ → 3′ cross-links account
for ∼80% of peptidoglycan extracted from M. tuberculosis in
stationary phase, a form of nonreplication.50 One of the
nonclassical L,D-transpeptidases, LdtMT2, plays a role in M.
tuberculosis virulence in a mouse model of infection.51
Meropenem and other carbapenems bind recombinant
LdtMT1,2,4,5.
52 However, there are additional covalent targets
of β-lactams, such as signal peptidases and proteases.53−55
Thus, we anticipate that β-lactams that specifically target
nonreplicating populations may have either single or multiple
canonical or noncanonical targets.
Two of the cephalosporins with activity against non-
replicating M. tuberculosis were stable in PBS and in
nonreplicating medium, whether or not the medium contained
NaNO2. An equipotent compound, 3, was unstable. Thus, 3
may have entered the bacilli or otherwise exerted its bactericidal
effect before its structure was transformed in the extracellular
medium.
In animal and human tuberculosis, M. tuberculosis often
resides in macrophages,56 and the ability to kill intracellular
bacilli is an important feature of antimycobacterial compounds.
Two of the nonreplicating active cephalosporins, compounds 1
and 5, killed intracellular M. tuberculosis but with differential
dependences on immune activation. Immune activation of M.
tuberculosis-infected macrophages leads to profound changes of
the phagosomal microenvironment that are anticipated to lead
to growth arrest. These changes include phagosomal acid-
ification to approximately pH 4.5 and induction of iNOS, which
produces nitric oxide.14,15 M. tuberculosis exhibits variable
behavior in mouse bone marrow-derived macrophages, ranging
from subexponential replication in nonactivated macrophages
to slower replication, no net change in CFU, or a modest
decline in CFU in activated macrophages. An inhibitor of
dihydrolipoamide acyltransferase (DlaT) selectively kills M.
tuberculosis and M. bovis BCG in vitro when they are
nonreplicating, and this compound is effective against M.
bovis BCG in activated macrophages.17 Likewise, compound 5
killed intracellular M. tuberculosis when the macrophages were
immune stimulated, consistent with our hypothesis that
compound 5 exerts activity in an acidic, nitrosative phagosome.
However, compound 1 killed intracellular M. tuberculosis both
in the absence and presence of IFNγ activation and thus may
possess some activity against replicating M. tuberculosis at the
concentrations tested.
■ SUMMARY
The potential ability of β-lactams to treat TB has been
suggested for many years but has only recently gained
substantial notice with the report of promising results using
Meropenem in human trials.45,46 It would be of considerable
interest to test the role of β-lactams that target nonreplicating
M. tuberculosis in TB therapy in combination with agents active
against replicating M. tuberculosis. Cephalosporins with activity
against nonreplicating M. tuberculosis identified in this study, 5
and 1, were nontoxic, stable in cell-free medium, stable at pH 2
and 7, soluble at pH 7.4, predicted to be membrane-permeable,
active in macrophages, and inactive against the other bacterial
and yeast species tested. Compounds 1 and 5 were relatively
stable when incubated with human liver microsomes. Although
compounds 1 and 5 were highly labile in mouse plasma, they
were more stable in human plasma with half-lives of 2−3 h.
Some analogues of compound 5 were active in the ng/mL
range. We are continuing to study the SAR of 5 while seeking
its targets.
■ EXPERIMENTAL SECTION
General Procedure for Synthesis of Esters: Propyl (6R,7R)-3-
Methyl-8-oxo-7-(2-phenoxyacetamido)-5-thia-1-azabicyclo-
[4.2.0]oct-2-ene-2-carboxylate (1).37 To (6R,7R)-3-methyl-8-oxo-
7-(2-phenoxyacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carbox-
ylic acid (197.0 mg, 0.57 mmol) was added sodium bicarbonate (48
mg, 0.57 mmol) and a minimal amount of water (6.0 mL) to dissolve
the starting material. The mixture was stirred at rt for 30 min until all
solids were dissolved and then frozen and lyophilized. DMF (10.0 mL)
was slowly added followed by 1-iodopropane (0.55 mL, 5.7 mmol).
The reaction was stirred at rt for 16 h, then quenched with water, and
extracted twice with Et2O. The Et2O layers were combined and then
washed 3 times with water and once with brine solution. The organic
layer was dried (Na2SO4), filtered, and concentrated. The residue was
purified via MPLC (silica, 30% EtOAc/hexanes → 70% EtOAc/
hexanes) to afford the title compound (130.0 mg, 59% yield). [α]D
25
+71.2 (c 1.45, CH2Cl2); IR (film) νmax 1780, 1721, 1687, 1524, 1494,
1228, 755 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.34 (m, 2H), 7.30 (s,
1H), 7.05 (tt, J = 7.7, 1.0 Hz, 1H), 6.94 (m, 2H), 5.88 (dd, J = 9.2, 4.7
Hz, 1H), 5.04 (d, J = 4.8 Hz, 1H), 4.58 (s, 2H), 4.24 (m, 2H), 3.53
(dd, J = 18.3, 1.0 Hz, 1H), 3.22 (d, J = 18.3 Hz, 1H), 2.15 (s, 3H), 1.75
(h, J = 7.4 Hz, 2H), 0.99 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz,
CDCl3) δ 168.80, 164.03, 162.35, 157.03, 130.88, 129.96, 129.80,
123.01, 122.52, 115.05, 114.90, 67.51, 67.25, 58.44, 56.94, 30.27,
22.03, 20.18, 10.61; HRMS (ESI-TOF) calcd for C19H22N2O5SNH4
+
[M + NH4]
+ 408.1588, found 408.1605.
General Procedure for Synthesis of Oxadiazoles: N-((6R,7R)-
3-Methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)-8-oxo-5-thia-1-
azabicyclo[4.2.0]oct-2-en-7-yl)-2-phenoxyacetamide (5). To a
solution of 2,4-dinitrophenol (1.03 g, 5.61 mmol) in CH2Cl2 (10 mL)
was sequentially added (6R,7R)-3-methyl-8-oxo-7-(2-phenoxyacetami-
do)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (1.92 g, 5.5
mmol) in a minimal amount of 1,4-dioxane (8 mL) and DCC (1.15 g,
5.6 mmol) in 8 mL of CH2Cl2. The mixture was stirred at rt for 30
min, after which the mixture was filtered through a plug of cotton to
Scheme 1. Synthetic Route for the Preparation of Ester and
Oxadiazole Analogues
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Table 5. SAR of C-2 Cephalosporin Oxadiazolesb
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remove the urea. To the filtrate was then added ethylamidoxime
(411.0 mg, 5.6 mmol) in CH2Cl2 (7 mL), and the mixture was stirred
at rt for 4 h. The mixture was then washed twice with sat. aq NaHCO3,
filtered, and concentrated. The residue was then placed in a vacuum
oven at 110 °C for 16 h, and the resulting residue was purified via
MPLC (silica, 100% hexanes → 60% EtOAc/hexanes) to afford the
title compound as an orange solid (703.2 mg, 52% yield). [α]D
24 +79.6
(c 0.72, CH2Cl2); IR (film) νmax 1775, 1493, 1331, 1216, 754, 732, 690
cm−1; 1H NMR (400 MHz, CDCl3) δ 7.35 (m, 3H), 7.06 (tt, J = 7.4,
1.0 Hz, 1H), 6.96 (m, 2H), 5.95 (dd, J = 9.1, 4.8 Hz, 1H), 5.16 (d, J =
4.7 Hz, 1H), 4.60 (s, 2H), 3.61 (d, J = 18.4 Hz, 1H), 3.35 (d, J = 18.3
Hz, 1H), 2.49 (s, 3H), 2.25 (s, 3H); 13C NMR (126 MHz, CDCl3) δ
Table 5. continued
aThese data were from a 3-day exposure to compound. bn.d. = not determined. n.t. = not tested.
Table 6. Predicted Properties of Representative C-2 Ester and Oxadiazole Cephalosporinsa
aMW, molecular weight; HDB, H-bond donor; HBA, H-bond acceptor; PSA, polar surface area.
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168.79, 167.63, 164.56, 156.99, 130.93, 129.98, 122.56, 117.45, 114.90,
67.25, 58.73, 57.25, 30.02, 20.40, 11.92. HRMS (ESI-TOF) calcd for
C18H19N4O4S
+ [M + H]+ 387.1122, found 387.1088.
Strains and Growth Conditions. Mycobacterial strains and
media were prepared as described.21,35 Briefly, wild-type M. tuberculosis
H37Rv was cultivated at 20% O2 and 5% CO2 in Middlebrook 7H9
bacteriologic medium containing 0.2% glycerol, tyloxapol (0.02%), and
10% OADC supplement, and the M. tuberculosis strain mc26220
(ΔpanCDΔlysA)38,57 was grown in similar medium with minor
modifications: additional glycerol (final: 0.5%), OADC supplement,
casamino acids (0.05%), L-lysine (240 μg/mL), and pantothenate (24
μg/mL). Cells were rendered nonreplicating at 1% O2 and 5% CO2 in
a Sauton’s-based medium (per liter: 0.5 g of KH2P04, 0.5 g of MgS04,
0.05 g of ferric ammonium citrate, BSA (0.5%), NaCl (0.085%),
tyloxapol (0.02%), L-lysine (240 μg/mL), pantothenate (24 μg/mL),
butyrate (0.05%), and 0.5 mM NaNO2).
High Throughput Screen. Molecules from the University of
Kansas in-house library were screened using a reported protocol21,35
with minor modifications. For the replicating screen, 500 nL test agent
was added to 50 μL of replicating M. tuberculosis mc26220 at an OD580
= 0.01, giving a final concentration of 20 μg/mL and 1% DMSO. After
7 days of incubation at 20% O2 and 5% CO2, the OD580 was
determined. For the nonreplicating screen, M. tuberculosis mc26220
was washed 2× in PBS containing tyloxapol (0.02%; PBS-Tyl) and
resuspended in nonreplicating medium containing 0.5 mM NaNO2,
and 15 μL of cells were dispensed into 384-well tissue culture plates
(Greiner, reference 781091). Cells were exposed to 150 nL of test
compounds in DMSO, and plates were incubated for 7 days at 1% O2
and 5% CO2. After 3 days of exposure to test agents, M. tuberculosis in
each well was diluted 5-fold by the addition of 60 μL of fresh
replicating medium using a reagent dispenser (ThermoScientific),
which also served to mix cells. After 7 days of outgrowth at 20% O2
and 5% CO2, the OD580 was determined. Primary screening hits and
downstream assay data were managed using the CDD Vault from
Collaborat ive Drug Discovery (Burl ingame, CA. www.
collaborativedrug.com)58 and JChem for Excel and MarvinView
(ChemAxon).
Activity against Replicating and Nonreplicating M. tuber-
culosis. For minimal inhibitory concentration (MIC) assays,
compounds were serially diluted 2-fold in DMSO from 10 to 0.04
mM using a PerkinElmer Janus robot with a P30 row/column MDT
head to make 100× compound source stocks in Greiner compound
plates (384-well small volume conical well, reference number 784201).
Compounds were then distributed into 384-well replicating and
nonreplicating assays with M. tuberculosis mc26220 in 384-well
microplates as described above. For colony forming unit assays,
experiments were set up using wild-type M. tuberculosis single cell
suspensions in 96-well tissue culture-treated plates (Corning). At
select time points, aliquots of cells were serially diluted in PBS-Tyl and
spread on Middlebrook 7H11 agar plates containing a 10% OADC
supplement. Colonies were enumerated ∼3 weeks postplating. The
minimal bacteriocidal concentration leading to 99% reduction in
colony forming units (MBC99) was extrapolated from CFU data.
HepG2 Toxicity Assays. Toxicity assays using the human
hepatoma cell line HepG2 were as described.59 Briefly, HepG2 cells
were propagated in Dulbecco’s modified Eagle medium (DMEM)
containing 10% fetal bovine serum (FBS), pyruvate, glutamine, and
Table 7. Stability and Solubility of 4, 1, and 5
cephalexin 4 1 5
pH 2 stability (%)a 73.7 110 102
pH 7 stability (%)a 102 133 101
pH 12 stability (%)a 0.000 0.000 0.000
solubility (μM/pH 7.4)b 75.8 22.7 83.7
aPercent remaining after a 4 h incubation at 37 °C. bDetermined after
shaking at room temperature for 4 h.
Table 8. Preliminary Pharmacokinetic Properties of 4, 1, and
5
cephalexin 4 1 5
PAMPA (mean Pe(10−6) cm/s) <0.0001a 7.28 13.4
PAMPA (log Pe) <−9.99 −5.15 −4.87
mouse liver microsomes (t1/2,
minutes)b
stablec <5 <5






human liver microsomes (t1/2,
minutes)
stable 86.1 76.3
human liver microsomes, CLint
(μL/min/mg protein)
stable 8.07 9.13
aNo compound detected. bBoth compounds 1 and 5 unstable in assay
conditions. cNo metabolism observed at ≤60 min.
Figure 4. Stability of compounds 1 and 5 in plasma. Compounds 1, 5,
and cephalexin (4) were tested for stability in mouse (a) and human
(b) plasma at the indicated time points. Stability was inferred by
monitoring the parent ion. One of two similar experiments.
Compound 1 was tested once in human plasma.
Figure 5. Bactericidal activity of compounds 1 and 5 for non-
replicating M. tuberculosis. Nonreplicating wild-type M. tuberculosis at
an OD580 of 0.01 was exposed to compounds for 7 days, and surviving
bacilli were enumerated on 7H11-OADC agar plates. The inoculum is
shown in yellow. The limit of detection was 1 colony arising from 10
μL of undiluted sample. Error bars represent standard deviations of
triplicates. One of two similar experiments.
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nonessential amino acids. HepG2 cells were incubated for 2 days with
DMSO vehicle control or test compounds (≤1% DMSO final) at 3000
cells/well in 384-well tissue culture plates (Greiner reference 781091).
Cellular viability was determined after 2 days by measuring ATP
content with a CellTiter-Glo kit (Promega).
Microbial Spectrum. Select compounds were tested for activity
against a panel of replicating Gram positive and Gram negative
bacteria (Mycobacterium smegmatis, Staphylococcus aureus, Escherichia
coli, and Pseudomonas aeruginosa) and yeast (Candida albicans).
Bacteriologic medium and assay conditions were as described.21 In
brief, 200 μL of cells at an OD580 of 0.01 in a sterile, clear tissue
culture-treated Corning 96-well plate were exposed to DMSO or drug,
and growth was determined by optical density.
Stability Assay. Compounds were dissolved at 50 μg/mL in cell-
free PBS (pH 7.4) or cell-free nonreplicating medium (pH 5.0)
containing or not 0.5 mM NaNO2. Poorly soluble compounds were
dissolved at 5 μg/mL and in a 50:50 (vol:vol) solution of acetonitrile
and PBS, or acetonitrile and nonreplicating medium containing or not
0.5 mM NaNO2. The nonreplicating medium was as described above
except that BSA, tyloxapol, lysine, and pantothenate were omitted.
Solutions containing acetonitrile had their pH adjusted to 5.0 (the
additional acetonitrile increased the pH from 5.0 to 5.8). Samples were
incubated at 37 °C, and aliquots were removed every 12 h for analysis
by LC-MS. Data represent percent remaining of the parent compound
compared to that at the start of the experiment.
Cheminformatics. Tanimoto similarity between molecules and
cheminformatic analysis of chemical properties (including ClogP
Figure 6. Potentiation of activity of cephalosporins against nonreplicating M. tuberculosis by reactive nitrogen species. Wild-type M. tuberculosis was
resuspended at an OD580 of 0.1 in nonreplicating medium containing indicated concentrations of NaNO2 (0−1 mM) and dispensed into separate
microtiter plates for each NaNO2 concentration. Cells were then exposed to (a) 1 or (b) rifampicin for 7 days, after which a standard outgrowth
assay was initiated to estimate the number of surviving cells. In a separate experiment, nonreplicating M. tuberculosis at a standard OD580 of (c) 0.1 or
lower inoculum of OD580 of (d) 0.01 were treated with either 1 (red) or 5 (blue) in the presence or absence of 0.5 mM NaNO2 for 7 days. CARA
fluorescence provides an estimate of mycobacterial viability; complete loss of fluorescence is associated with ≥2−3 log10 CFU reduction.
Figure 7. Bactericidal activity of (a) 1 and (b) 5 against intracellular M. tuberculosis. Mouse bone marrow-derived macrophages activated or not with
50 ng/mL of IFNγ were infected with wild-type M. tuberculosis. After a 4 h period for bacterial uptake, macrophages were washed and treated with
100 μg/mL of 1 or 5 for (a) 4 or (b) 3 days. Morphology of the macrophages was not affected by addition of 1 or 5 at the concentrations shown.
One of five similar experiments.
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values) were determined in Collaborative Drug Discovery (CCD)
(Burlingame, CA; www.collaborativedrug.com)58 using ChemAxon
software.
Physicochemical, Permeability, and Metabolism Studies.
These assays were performed by BioDuro (Shanghai, China). Mouse
and human liver microsomal stability was assayed in triplicate at 0, 15,
30, 45, and 60 min.
Plasma Stability. Cephalosporins 1, 5, and cephalexin were spiked
into lithium heparin-treated human and CD-1 mouse plasma
(bioreclammation) at 1 μg/mL. Spiked samples were incubated at
37 °C, and extractions were performed at 5, 15, 30, 60, and 180 min.
The reactions were quenched and proteins precipitated at each time
point by adding 20 μL of spiked plasma to 200 μL of extraction
solvent containing methanol/acetonitrile (1:1; vol/vol) and 10 ng/mL
of verapamil (Toronto Research Chemicals, Inc.) as an internal
standard (IS). In addition, 20 μL of 1:1 acetonitrile/water (ACN/
H2O; vol/vol) were added. A reference sample was created by adding
20 μL of unspiked plasma to 200 μL of the extraction solvent. After
the plasma enzymes were denatured by the extraction solvent, 20 μL
of a 1 μg/mL solution in 1:1 ACN/H2O was added to the reference
sample. Extracted samples were vortexed for 5 min and then
centrifuged at 3000 rpm for 5 min. Then, 100 μL of extract was
transferred to 100 μL of ddH20 for LC-MS analysis. LC-MS analysis
was performed with an Agilent 1260 liquid chromatography system
coupled to a 4000 Qtrap mass spectrometer (AB Sciex) in multiple
reaction monitoring (MRM) mode with positive electrospray
ionization (ESI) and an Agilent column, SB-C8, 2.1 × 30 mm, 3.5
μm. Mobile phase A was 0.1% formic acid in 100% H2O, and mobile
phase B was 0.1% formic acid in 100% acetonitrile. Injection volumes
were routinely 2 μL. The ions monitored were compound 1 (m/z
387.1/195.9), compound 5 (391.1/199.9), cephalexin (348.1/158.1),
and verapamil (455.4/165.2). The percentage remaining was
determined at each time point by dividing the sample analyte/IS
peak area ratio by the reference sample analyte/IS peak area ratio.
Charcoal Agar Resazurin Assay (CARA). The CARA was used as
described.42 In brief, 10 μL aliquots from replicating or nonreplicating
MIC90 assay plates were removed and spotted onto microplates
containing 200 μL of 7H11-OADC-charcoal agar in each well. The
microplates were then incubated for 7−10 days at 37 °C at 20% O2
and 5% CO2. The film of bacterial growth (microcolonies) on the
microplates was semiquantitated by the addition of 40 μL of a 1:1 (v/
v) mixture of Alamar blue (AB) and Tween80 (TW80) and 1 h of
further incubation at 37 °C at 20% O2 and 5% CO2. In some cases, if
the CARA microplate appeared dry, all wells were prewetted with 40
μL of PBS prior to the addition of the AB:TW80 developing solution.
Fluorescence was determined by top-read with excitation at 530 nm
and emission at 590 nm. The CARA-minimal bactericidal concen-
tration leading to ≥99% loss in CFUs (CARA-MBC≥99) was estimated
as the lowest concentration of drug leading to complete loss of Alamar
blue fluorescence.
Macrophage Infections. Primary bone marrow-derived macro-
phage infections were performed as described.17,60−62 In brief, ∼1 ×
105 macrophages isolated from 8-week old female C57Bl6 mice were
grown in 48-well plates in DMEM supplemented with 4.5 g/L of
glucose, 0.584 g/L of L-glutamine, 1 mM pyruvate, 10% FBS, and 10%
L-cell conditioned medium containing or not 50 ng/mL of
recombinant mouse IFNγ and infected with wild-type M. tuberculosis
H37Rv at a multiplicity of infection of 1−5. Log phase wild-type M.
tuberculosis was allowed to infect macrophages for 4 h, after which
medium and extracellular M. tuberculosis were removed by two washes
with PBS and replaced with fresh medium containing compounds or
not at 1% DMSO. At the times indicated, macrophages were washed
and lysed with PBS supplemented with 0.5% Triton X-100. Surviving
bacilli were enumerated on 7H11-OADC agar plates. Macrophage
supernatants were assayed for nitrite with the Greiss assay.
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